The German company has received permission for the first clinical trials of a vaccine against coronavirus infection, the Paul Ehrlich Institute for vaccines and biomedical drugs reported on Wednesday, April 22.
“The Paul Ehrlich Institute-the Federal Institute for vaccines and biomedical drugs-has approved the first clinical trial of the COVID-19 vaccine in Germany. The authorization came as a result of a thorough assessment of the potential benefit and risk profile for the vaccination candidate,” the report said.
It is noted that scientific consultations were held with the developer of the drug BioNTech for four days.
“Testing of vaccine candidates in humans is an important milestone on the road to safe and effective COVID-19 vaccines for the population in Germany and abroad,” the organization said.
A day earlier, Alexander Myasnikov, a representative of the information center for monitoring the situation with coronavirus, said that the Russian Ministry of health’s coronavirus vaccine is under investigation, and the pre-clinical stage is planned to be completed by the end of may.
On April 20, Natalia Dumchenko, a researcher at the Vector State research center, also said that clinical trials of the coronavirus vaccine will begin in June. She clarified that this stage can be started only after obtaining the permission of the Ministry of health of the Russian Federation and approval by the ethics Committee of both the Ministry of health and the research clinical center.
On the same day, Russian President Vladimir Putin instructed the Ministry of health to speed up the development of a coronavirus vaccine. The head of state also assured that if necessary, the authorities will provide support and allocate additional resources for the development of a vaccine.
According to Worldometer on April 22, more than 2.5 million cases of coronavirus infection were recorded in the world, 177.7 thousand patients died, and 695.3 thousand people recovered.
All up-to-date information on the situation with coronavirus is available on the websites stopkoronavirus.RF and accessvsem.RF. the hotline For coronavirus: 8 (800) 2000-112. In addition, information is available via the hashtag #Myvote.